A US pharmaceutical company is working on development of novel ovarian cancer drug.
Patient, Andrea, who is a US resident, exhausted all standard treatment options, her doctors say
her best hope now is a new class of cancer drugs called PARP inhibitors (BMN 673).
She has been given six months to live. She would like to have the new drug treatment and the
FDA has said that this patient does qualify to seek compassionate use of this drug, but company
won’t provide it and they don’t have to.
A. Andrea Sloan Case – CNN Story https://edition.cnn.com/2013/09/28/health/compassionate-drug-use/index.html
B. Andrea Sloan Case – Change.Org Petition http://www.change.org/petitions/biomarin-pharmaceutical-give-andrea-sloan-andi-sloan-access-to-the-cancer-drug-that-could-save-her-life
Address each of the following positions:
•
FDA’s Position
Identify and outline at least three legal and social policy arguments as to why Andrea
should be allowed to receive the drug.
